Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry-Reference-Cited by-同舟云学术

Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry

Published:2016-03-24 Issue:4 Volume:68 Page:432-439
ISSN:2151-464X
Container-title:Arthritis Care & Research
language:en
Short-container-title:Arthritis Care & Research

Author:

Favalli Ennio Giulio¹,Pregnolato Francesca²,Biggioggero Martina³,Becciolini Andrea¹,Penatti Alessandra Emiliana³,Marchesoni Antonio¹,Meroni Pier Luigi⁴

Affiliation:

1. Gaetano Pini Institute; Milan Italy

2. Experimental Laboratory of Immunological and Rheumatologic Researches, IRCCS Istituto Auxologico Italiano; Milan Italy

3. University of Milan and Gaetano Pini Institute; Milan Italy

4. University of Milan and IRCCS Istituto Auxologico Italiano; Milan Italy

Funder

Ricerca Corrente 2014, Istituto Auxologico Italiano

Publisher

Wiley

Subject

Rheumatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/acr.22788/fullpdf

Reference29 articles.

1. Infliximab and methotrexate in the treatment of rheumatoid arthritis: Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group;Lipsky;N Engl J Med,2000

2. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial;Klareskog;Lancet,2004

3. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial;Keystone;Arthritis Rheum,2004

4. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment;Breedveld;Arthritis Rheum,2005

5. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial;Emery;Lancet,2008

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug retention of biologic and targeted synthetic disease-modifying antirheumatic drugs in Korean patients with seropositive rheumatoid arthritis;The Korean Journal of Internal Medicine;2024-09-01

2. Drug survival analysis of etanercept compared with monoclonal antibody tumour necrosis factor-α inhibitors in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a propensity score-matched analysis from the Czech ATTRA registry;Scandinavian Journal of Rheumatology;2024-08-06

3. Effect of disease duration on the use of tofacitinib: a real-world study in elderly patients with rheumatoid arthritis;Clinical Rheumatology;2024-08-02

4. Jin-Gu-Lian Capsule Did Not Significantly Improve Clinical Value in Rheumatoid Arthritis Therapy: A Real-World Study;Journal of Inflammation Research;2024-08

5. Can we predict the risk factors for switching due to ineffectiveness in the first year of therapy with bDMARD in patients with rheumatoid arthritis?;Reumatología Clínica;2024-08